Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Nils Picker, MSc, Alexander T Cohen, MBBS, MSc, MD, Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Thomas Wilke, Prof. Dr. rer. oec.

Blood (2019) 134 (Supplement_1): 2159.

https://doi.org/10.1182/blood-2019-128095

Published: 2019

Journal Articles

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Alexander T Cohen, MBBS, MSc, MD

Blood (2019) 134 (Supplement_1): 2161.

https://doi.org/10.1182/blood-2019-126810

Published: 2019

Journal Articles

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD, Luise Tittl, Christiane Naue, MD, Jan Beyer-Westendorf, MD

Blood (2019) 134 (Supplement_1): 3667.

https://doi.org/10.1182/blood-2019-126535

Published: 2019

Journal Articles

NOAC Therapy Is Also Effective and Safe in Patients Older Than 80 Years — Results of the Prospective Dresden NOAC Registry (NCT01588119)

Jan Beyer-Westendorf, MD, Luise Tittl, Christiane Naue, MD, Sandra Marten, MD

Blood (2018) 132 (Supplement 1): 422.

https://doi.org/10.1182/blood-2018-99-118081

Published: 2018

Journal Articles

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study

Craig I. Coleman, PharmD, Alexander G. Turpie, MD, Thomas J. Bunz, PharmD, PhD, Jan Beyer-Westendorf, MD, William L Baker, PharmD

Blood (2018) 132 (Supplement 1): 1241.

https://doi.org/10.1182/blood-2018-99-114133

Published: 2018

Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD

Blood (2017) 130 (Supplement 1): 218.

https://doi.org/10.1182/blood.V130.Suppl_1.218.218

Published: 2017

Journal Articles

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism

Christine G. Kohn, BS, PharmD, Gary H. Lyman, MD MPH, FRCP, Jan Beyer-Westendorf, MD, Alex C. Spyropoulos, MD, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2017) 130 (Supplement 1): 3717.

https://doi.org/10.1182/blood.V130.Suppl_1.3717.3717

Published: 2017

Journal Articles

Splanchnic Vein Thrombosis Treatment with Rivaroxaban - a Case Series from the Prospective Dresden Noac Registry (NCT01588119)

Sven Pannach, MD, Luise Tittl, B.Sc., Sandra Marten, MD, Sebastian Endig, MD, Jan Beyer-Westendorf, MD

Blood (2017) 130 (Supplement 1): 1109.

https://doi.org/10.1182/blood.V130.Suppl_1.1109.1109

Published: 2017

Journal Articles

Effectiveness and Safety of Rivaroxaban Versus Warfarin for Treatment of Venous Thromboembolism in Patients with Known Primary Hypercoagulable States

Craig I. Coleman, PharmD, Alexander G. G. Turpie, MD, Thomas J. Bunz, PharmD, PhD, Jan Beyer-Westendorf, MD

Blood (2017) 130 (Supplement 1): 1113.

https://doi.org/10.1182/blood.V130.Suppl_1.1113.1113

Published: 2017

Journal Articles

Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy

Sven Pannach, MD, Julia Goetze, Luise Tittl, B.Sc., Thomas Schreier, Sandra Marten, MD, Jochen Hampe, MD, Jan Beyer-Westendorf, MD

Blood (2016) 128 (22): 141.

https://doi.org/10.1182/blood.V128.22.141.141

Published: 2016

Journal Articles

Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119)

Loretta Keller, Sandra Marten, MD, Judith Hecker, Sebastian Werth, MD, Luise Tittl, B.Sc., Jan Beyer-Westendorf, MD

Blood (2016) 128 (22): 2618.

https://doi.org/10.1182/blood.V128.22.2618.2618

Published: 2016

Journal Articles

Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial

Jan Beyer-Westendorf, MD, Sebastian Schellong, MD, Horst Gerlach, MD, Katja Jersemann, Eberhard Rabe, MD, Kurtulus Sahin, Rupert Bauersachs, MD PhD

Blood (2016) 128 (22): 85.

https://doi.org/10.1182/blood.V128.22.85.85

Published: 2016

Journal Articles

Pattern and Management of ISTH Major Bleeding Complications with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD, Luise Tittl, B.Sc., Katharina Daschkow, Jan Beyer-Westendorf, MD

Blood (2015) 126 (23): 892.

https://doi.org/10.1182/blood.V126.23.892.892

Published: 2015

Journal Articles

Pattern and Management of Intracranial Haemorrhage with Rivaroxaban or Dabigatran Compared to Vitamin K Antagonists - Results of the Prospective Dresden Noac Registry

Sandra Marten, MD, Luise Tittl, B.Sc., Katharina Daschkow, Jan Beyer-Westendorf, MD

Blood (2015) 126 (23): 1127.

https://doi.org/10.1182/blood.V126.23.1127.1127

Published: 2015

Journal Articles

Outcome of Noac Exposure during Pregnancy (...and the problem of event reporting...)

Jan Beyer-Westendorf, MD, Sandra Marten, MD, Franziska Michalski, MD

Blood (2015) 126 (23): 1125.

https://doi.org/10.1182/blood.V126.23.1125.1125

Published: 2015

Journal Articles

Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD, Luise Tittl, B.Sc., Katharina Daschkow, Jan Beyer-Westendorf, MD

Blood (2015) 126 (23): 1131.

https://doi.org/10.1182/blood.V126.23.1131.1131

Published: 2015

Journal Articles

Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry

Jan Beyer-Westendorf, MD, Kati Förster, Franziska Ebertz, Vera Gelbricht, Franziska Michalski, Luise Tittl, Norbert Weiss, Prof.

Blood (2014) 124 (21): 4264.

https://doi.org/10.1182/blood.V124.21.4264.4264

Published: 2014

Journal Articles

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Franziska Michalski, Sebastian Werth, MD, Christina Köhler, MD, Luise Tittl, Katharina Daschkow, Jan Beyer-Westendorf, MD

Blood (2014) 124 (21): 2876.

https://doi.org/10.1182/blood.V124.21.2876.2876

Published: 2014

Journal Articles

Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up

Walter Ageno, MD, Nicoletta Riva, Sam Schulman, MD PhD, Jan Beyer-Westendorf, MD, Soo-Mee Bang, Marco Senzolo, Elvira Grandone, Giovanni Barillari, Matteo Di Minno, Rita Duce, Alessandra Malato, Rita Santoro, Daniela Poli, Peter Verhamme, MD PhD, Ida Martinelli, Pieter W. Kamphuisen, MD PhD, Francesco Dentali, MD

Blood (2014) 124 (21): 592.

https://doi.org/10.1182/blood.V124.21.592.592

Published: 2014

Journal Articles

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Jan Beyer-Westendorf, MD, Franziska Michalski, Sebastian Werth, MD, Luise Tittl, Christina Köhler, MD, Norbert Weiss, Prof.

Blood (2014) 124 (21): 1538.

https://doi.org/10.1182/blood.V124.21.1538.1538

Published: 2014

NARROW

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

NOAC Therapy Is Also Effective and Safe in Patients Older Than 80 Years — Results of the Prospective Dresden NOAC Registry (NCT01588119)

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism

Splanchnic Vein Thrombosis Treatment with Rivaroxaban - a Case Series from the Prospective Dresden Noac Registry (NCT01588119)

Effectiveness and Safety of Rivaroxaban Versus Warfarin for Treatment of Venous Thromboembolism in Patients with Known Primary Hypercoagulable States

Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy

Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119)

Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial

Pattern and Management of ISTH Major Bleeding Complications with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)

Pattern and Management of Intracranial Haemorrhage with Rivaroxaban or Dabigatran Compared to Vitamin K Antagonists - Results of the Prospective Dresden Noac Registry

Outcome of Noac Exposure during Pregnancy (...and the problem of event reporting...)

Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)

Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only